Rein Therapeutics Stock (NASDAQ:RNTX)

Financials Chart

Previous Close

$1.76

52W Range

$1.35 - $4.50

50D Avg

$1.91

200D Avg

$2.51

Market Cap

$39.15M

Avg Vol (3M)

$38.77K

Beta

2.12

Div Yield

-

RNTX Company Profile

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.

Industry

Medical - Pharmaceuticals

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

11

IPO Date

Jun 29, 2017

Website

RNTX Performance

RNTX Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	$-65.11K	$-16.28K	$-27.65K
Net Income	$-62.88K	$-15.73K	$-27.33K
EBITDA	$-28.05K	$-15.23K	$-27.48K
Basic EPS	$-3.51	$-3.42	$-6.02
Diluted EPS	$-3.51	$-3.42	$-6.02

Fiscal year ends in Dec 24 | Currency in USD